Probiotics in women’s health
The human probiotics market size is anticipated to surpass USD 5 billion by 2024 owing to its increasing demand. Probiotics are used to treat Urinary tract infections, diabetes, diarrhea, vulvovaginal candidiasis, and bacterial vaginosis in women. Several in vitro and in vivo studies support the beneficial effect of some strains of lactobacilli on the restoration of the vaginal flora and the prevention of recurrent UTIs.
Related Conference of Probiotics in women’s health
September 22-30, -0001
11th International Conference on Chronic Obstructive Pulmonary Disease (COPD)
Amsterdam, Netherlands
December 05-06, 2022
14th International Conference on Chronic Obstructive Pulmonary Disease Conference
Rome, Italy
Probiotics in women’s health Conference Speakers
Recommended Sessions
- Microbiome
- Pediatric and Infant Health
- Pre and Probiotics futures
- Prebiotics and Diet
- Prebiotics old and new
- Probiotics in Aquaculture
- Probiotics in food security
- Synbiotic
- Food and Fermentation
- Formulations and Production
- Gut Bacteria on COVID Severity
- Gut microbiota
- Microbiota from womb to adult
- Microbiota Protection and Resilience
- New Methods and New Equipment
- Nutrition and Probiotics
- Preterm and term Newborns Probiotics
- Probiotics and COVID-19
- Probiotics in oral health and dentistry
- Probiotics in women’s health
Related Journals
Are you interested in
- Alpha 1 Antitrypsin Deficiency & COPD - Lung Diseases 2022 (Belgium)
- Asthma - Lung Diseases 2022 (Belgium)
- Asthma and Allergy - PULMONOLOGY 2022 (Japan)
- Cardio Pulmonary Disorders - Respiratory 2022 (France)
- Cardiopulmonary Disorders - Lung Diseases 2022 (Belgium)
- Cardiopulmonary Disorders - PULMONOLOGY 2022 (Japan)
- Chronic Obstructive Pulmonary Disease - Lung Diseases 2022 (Belgium)
- Chronic Obstructive Pulmonary Disease - Respiratory 2022 (France)
- Chronic Obstructive Pulmonary Disease - PULMONOLOGY 2022 (Japan)
- Clinical management of severe acute respiratory infection - Lung Diseases 2022 (Belgium)
- COVID-19 and Asthma - Respiratory 2022 (France)
- COVID-19 and Respiratory System - Respiratory 2022 (France)
- COVID-19 Treatment and Recovery - Lung Diseases 2022 (Belgium)
- Covid19 Vaccine and Lung Immunopathology - Lung Diseases 2022 (Belgium)
- Cystic Fibrosis - PULMONOLOGY 2022 (Japan)
- Cystic Fibrosis - Lung Diseases 2022 (Belgium)
- Depression and anxiety in COPD - Lung Diseases 2022 (Belgium)
- Diagnosis and Treatment of COPD - Lung Diseases 2022 (Belgium)
- Digital Health in Respiratory Care - Lung Diseases 2022 (Belgium)
- Effect of COVID-19 on Lungs - Lung Diseases 2022 (Belgium)
- Food and Fermentation - Probiotics 2022 (Japan)
- Formulations and Production - Probiotics 2022 (Japan)
- Genetic risk factor of COPD - Lung Diseases 2022 (Belgium)
- Gut Bacteria on COVID Severity - Probiotics 2022 (Japan)
- Gut microbiota - Probiotics 2022 (Japan)
- Idiopathic Pulmonary Fibrosis - PULMONOLOGY 2022 (Japan)
- Idiopathic Pulmonary Fibrosis - Lung Diseases 2022 (Belgium)
- Idiopathic Pulmonary Fibrosis - Respiratory 2022 (France)
- Innate Immunity and Lung Fibrosis - Lung Diseases 2022 (Belgium)
- Interstitial lung disease - PULMONOLOGY 2022 (Japan)
- Interstitial lung disease - Respiratory 2022 (France)
- Investigational Drugs and Other Therapies in the treatment of Respiratory Disease - Lung Diseases 2022 (Belgium)
- Lung cancer - Lung Diseases 2022 (Belgium)
- Lung cancer - Respiratory 2022 (France)
- Lung Cancer Diagnosis & Treatment - Lung Diseases 2022 (Belgium)
- Lung Diseases - PULMONOLOGY 2022 (Japan)
- Lung transplantation - Respiratory 2022 (France)
- Microbiome - Probiotics 2022 (Japan)
- Microbiota from womb to adult - Probiotics 2022 (Japan)
- Microbiota Protection and Resilience - Probiotics 2022 (Japan)
- New Methods and New Equipment - Probiotics 2022 (Japan)
- Nutrition and Probiotics - Probiotics 2022 (Japan)
- Obstructive sleep apnea - PULMONOLOGY 2022 (Japan)
- Obstructive sleep apnea - Respiratory 2022 (France)
- Occupational lung diseases - Respiratory 2022 (France)
- Pathology and Clinical Management of COPD - Lung Diseases 2022 (Belgium)
- Pediatric and Infant Health - Probiotics 2022 (Japan)
- Pediatric Pulmonology & Critical care - PULMONOLOGY 2022 (Japan)
- Pneumonia - Respiratory 2022 (France)
- Pneumonia - Lung Diseases 2022 (Belgium)
- Pre and Probiotics futures - Probiotics 2022 (Japan)
- Prebiotics and Diet - Probiotics 2022 (Japan)
- Prebiotics old and new - Probiotics 2022 (Japan)
- Preterm and term Newborns Probiotics - Probiotics 2022 (Japan)
- Probiotics and COVID-19 - Probiotics 2022 (Japan)
- Probiotics in Aquaculture - Probiotics 2022 (Japan)
- Probiotics in food security - Probiotics 2022 (Japan)
- Probiotics in oral health and dentistry - Probiotics 2022 (Japan)
- Probiotics in women’s health - Probiotics 2022 (Japan)
- Pulmonary Diseases and therapeutics - PULMONOLOGY 2022 (Japan)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2022 (France)
- Pulmonary Hypertension - PULMONOLOGY 2022 (Japan)
- Pulmonary Hypertension - Respiratory 2022 (France)
- Pulmonary Rehabilitation - Respiratory 2022 (France)
- Pulmonary Rehabilitation - Lung Diseases 2022 (Belgium)
- Pulmonary Rehabilitation - PULMONOLOGY 2022 (Japan)
- Respiratory Diseases - Lung Diseases 2022 (Belgium)
- Respiratory tract infections - PULMONOLOGY 2022 (Japan)
- Severe Acute Respiratory Syndrome (SARS) - Lung Diseases 2022 (Belgium)
- Sleep apnea - Lung Diseases 2022 (Belgium)
- Synbiotic - Probiotics 2022 (Japan)
- Tuberculosis - Respiratory 2022 (France)
- Tuberculosis - PULMONOLOGY 2022 (Japan)
- Tuberculosis - Lung Diseases 2022 (Belgium)